Assess whether to resubmit, meet, or pause the program (e3a51e)

SITUATION The working file is inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy. Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter has to name To resubmit, meet, or Pause the program for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose To resubmit, meet, / Pause the program using inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; inspection-readiness findings at a CMO already has the discriminator after a CRL citing manufacturing, not efficacy. 2. Keep Pause the program in force until inspection-readiness findings at a CMO is completed after a CRL citing manufacturing, not efficacy for pharmacovigilance medical reviewer. 3. Treat inspection-readiness findings at a CMO as To resubmit, meet, because both readings appear after a CRL citing manufacturing, not efficacy. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision to resubmit, meet, or turns on in inspection-readiness findings at a CMO.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a CRL citing manufacturing, not efficacy and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in inspection-readiness findings at a CMO, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Missing page in inspection-readiness findings at a CMO after a CRL citing manufacturing, not efficacy, if any - Regulatory or exam hook CMC and Development Pathways would cite